Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea

OBJECTIVE: This study estimated the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day (SFD) gained and the incremental cost per quality adjusted life year (QALY) gained when using levetiracetam (LEV) as add-on therapy from a third-party payer perspective. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Guk-Hee, Lee, Sang Keol
Formato: Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796067/
https://www.ncbi.nlm.nih.gov/pubmed/20046394
http://dx.doi.org/10.4306/pi.2009.6.3.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796067/
https://www.ncbi.nlm.nih.gov/pubmed/20046394
http://dx.doi.org/10.4306/pi.2009.6.3.185

Ejemplares similares